Makary Focuses On Chronic Disease Prevention, Rebuilding Trust In FDA During Senate Hearing

The FDA commissioner nominee offered few details on device policy, but said he was open to funding device postmarket surveillance through user fees. He also offered some defense of staff cuts while saying he would perform his own assessment before planning any more.